2Parish L C,Parish J L.Retapamulin:A new topical antibiotic for the treatment of uncomplicated skin infections[J].Drugs Today,2008,44(2):91-102.
3Bassetti M,Nicco E,Mikulska M.Why is community-associated MRSA spreading across the world and how will it change clinical practice[J].Int J Antimicrob Agents,2009,34(Suppl1):15-19.
4Mark E.Jones,James A.Karlowsky et al Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe:a guide to appropriate antimicrobial therapy[J] ,Int J Antimicrob Agents,2003,22:406-419.
5Long C B,Madan R P,Herold B C.Diagnosis and management of community-associated MRSA infections in children[J].Expert Rev Anti Infect Ther,2010,8(2):183-195.
6Hinckley J,Allen P J.Community-associated MRSA in the pediatric primary care setting[J].Pediatr Nurs.2008,34(1):64-71.
8Carbone M,Fera MT,Pennisi MG,et al.Activity of nine fluoroquinolones against strains of Bordetella bronchiseptica.Int J Antimicrob Agents,1999,12:355-358.
9Koning S,van Suijlekom-Smit LW,Nouwen JL,et al.Fusidic acid cream in the treatment of impetigo in general practice:double blind randomised placebo controlled trial.BMJ,2002,324:203-206.
10Johnston C.Topical 2% mupirocin versus 2% sodium fusidate ointment in the treatment of primary and secondary skin infections.J Am Acad Dermatol,1991,24:797-798.
